Mutations in BRAF, SMAD4, or TP53 were significantly correlated with the poor progression-free survival (BRAF: p = 3.62 × 10−3; SMAD4: p = 6.28 × 10−4; and TP53: p = 6.33 × 10−5) and overall survival (BRAF: p = 9.96 × 10−9; SMAD4: p = 5.96 × 10−3) of patients with colorectal cancer. Here, SMAD4 is linked to colorectal cancer.